# **1 TICTAC:** Target Illumination Clinical Trial Analytics with Cheminformatics

#### 2 Jeremiah I Abok<sup>1</sup>, Jeremy S Edwards<sup>1</sup>, Jeremy J Yang<sup>2\*</sup>

- <sup>3</sup> <sup>1</sup>Department of Chemistry & Chemical Biology, University of New Mexico, Albuquerque, NM,
- 4 87106 USA
- <sup>5</sup> <sup>2</sup>Division of Translational Informatics, Department of Internal Medicine, University of New Mexico
- 6 Health Sciences Center, Albuquerque, NM 87131, USA
- 7 \* Correspondence:
- 8 Corresponding Author
- 9 jjyang@salud.unm.edu
- 10 Keywords: Disease-Target<sub>1</sub>, Drug discovery<sub>2</sub>, Hypothesis generation<sub>3</sub>, Clinical trial data<sub>4</sub>,
- 11 Inference<sub>5</sub>.

#### 12 Abstract

- 13 Introduction
- 14 Identifying disease-target associations is a pivotal step in drug discovery, offering insights that guide
- 15 the development and optimization of therapeutic interventions. Clinical trial data serves as a valuable
- 16 source for inferring these associations. However, issues such as inconsistent data quality and limited
- 17 interpretability pose significant challenges. To overcome these limitations, an integrated approach is
- 18 required that consolidates evidence from diverse data sources to support the effective prioritization of
- 19 biological targets for further research.
- 20 Methods

21 We developed a comprehensive data integration and visualization pipeline to infer and evaluate 22 associations between diseases and known and potential drug targets. This pipeline integrates clinical 23 trial data with standardized metadata, providing an analytical workflow that enables the exploration of

- diseases linked to specific drug targets as well as facilitating the discovery of drug targets associated
- 25 with specific diseases. The pipeline employs robust aggregation techniques to consolidate multivariate
- 26 evidence from multiple studies, leveraging harmonized datasets to ensure consistency and reliability.
- 27 Disease-target associations are systematically ranked and filtered using a rational scoring framework
- 28 that assigns confidence scores derived from aggregated statistical metrics.
- 29 Results
- 30 Our pipeline evaluates disease-target associations by linking protein-coding genes to diseases and
- 31 incorporates a confidence assessment method based on aggregated evidence. Metrics such as
- 32 meanRank scores are employed to prioritize associations, enabling researchers to focus on the most
- 33 promising hypotheses. This systematic approach streamlines the identification and prioritization of
- 34 biological targets, enhancing hypothesis generation and evidence-based decision-making.
- 35 Discussion

36 This innovative pipeline provides a scalable solution for hypothesis generation, scoring, and ranking

37 in drug discovery. As an open-source tool, it is equipped with publicly available datasets and designed

38 for ease of use by researchers. The platform empowers scientists to make data-driven decisions in the

39 prioritization of biological targets, facilitating the discovery of novel therapeutic opportunities.

40

#### 41 **1** Introduction

42 ClinicalTrials.gov, managed by the U.S. National Library of Medicine (NLM), is a critical public repository that enhances transparency and accessibility in biomedical research. Established in 2000 43 44 under the Food and Drug Administration Modernization Act (FDAMA) of 1997, it serves as a 45 centralized platform for registering clinical studies and disseminating trial results, addressing 46 challenges related to data accessibility and reliability (Zarin et al., 2005; Tse et al., 2018). By 47 supporting clinical trial registration, the database provides researchers, policymakers, and the public 48 with comprehensive information about study designs, methodologies, and outcomes. Adherence to 49 global reporting requirements, including those mandated by the International Committee of Medical 50 Journal Editors (ICMJE) and the World Health Organization (WHO), ensures standardized practices 51 across the research community (Laine et al., 2007). ClinicalTrials.gov aligns with FAIR (Findable, 52 Accessible, Interoperable, and Reusable) principles (Wilkinson et al., 2016), employing standardized 53 data formats to enhance interoperability across platforms and disciplines. It curates metadata, 54 harmonizes submissions, and implements consistent reporting standards, addressing challenges such 55 as incomplete reporting, variability in trial methodologies, and inconsistencies in diagnostic criteria 56 (Riveros et al., 2013). The platform supports centralized trial registration and compliance with legal 57 and ethical mandates for transparency (Zarin et al., 2011). Its study results database enables researchers 58 to submit and access summary results, fostering evidence-based decision-making and mitigating 59 publication bias through the inclusion of unpublished trial data (Prayle et al., 2012). Furthermore, integration with global registries, such as the WHO's International Clinical Trials Registry Platform 60 (ICTRP), promotes harmonization and accessibility of clinical research data worldwide. Despite its 61 62 significant contributions, ClinicalTrials.gov faces challenges including variations in reporting quality, 63 delays in result submissions, and inconsistencies in terminology (DeVito et al., 2020). The platform 64 continues to evolve by introducing advanced data validation tools, promoting adherence to global 65 reporting standards, and collaborating with stakeholders to refine metadata frameworks and bridge 66 reporting gaps. As a robust and scalable platform for managing clinical trial data, ClinicalTrials.gov 67 fosters transparency and enhances research reproducibility while empowering the scientific community 68 and improving public trust.

69 The Database for Aggregate Analysis of ClinicalTrials.gov (AACT) was introduced to address 70 challenges in analyzing aggregate data from ClinicalTrials.gov, such as inconsistent data structures, 71 variability in nomenclature, and evolving data collection practices. Its purpose is to enhance the 72 usability of ClinicalTrials.gov data by consolidating and normalizing information, enabling more 73 effective aggregate analysis, policy studies, and systematic evaluations of clinical trial attributes and 74 trends (Tasneem et al., 2012). AACT transforms raw clinical trial data into a structured, enriched, and 75 analyzable format, integrating Medical Subject Headings (MeSH) terms and advanced curation 76 techniques to ensure consistency and usability (Tasneem et al., 2012). By enabling systematic reviews, 77 policy analysis, and diverse applications, AACT plays a pivotal role in evaluating global trial trends, 78 aligning with FAIR principles, and driving innovation in clinical research. Despite challenges like 79 reliance on MeSH hierarchies and limited global representation, ongoing advancements in ontology

- 80 integration and interoperability aim to position AACT as an indispensable resource for the future of
- 81 clinical trial analysis.
- 82

83 The core principle of pharmacology is that drugs, whether small molecules or biologics are designed 84 to specifically interact with target molecules, often proteins, to modulate physiological processes and 85 influence disease progression (Moffat et al., 2017; Scannell et al., 2012). Advanced methods in the pharmaceutical industry facilitate the discovery and optimization of these drugs, addressing challenges 86 87 in efficacy, dosing, and safety for market approval (Hay et al., 2014). However, analysis of drug development pipelines reveals that insufficient efficacy, particularly in late-stage clinical trials, is a 88 89 primary cause of failure, often due to inadequate validation of the target's role in disease physiology 90 (Ledford, 2011; Liu et al., 2021). This highlights the need for rigorous evidence supporting target-91 disease associations to improve success rates and minimize costly late-stage failures (Dahlin et al., 92 2015). Traditionally, drug targets were selected based on experimental evidence linking their 93 modulation to disease outcomes (Muller & Milton, 2012). Recent advancements in high-throughput 94 technologies, such as sequencing, genotyping, and mass spectrometry, have enhanced our ability to 95 characterize biological samples, uncovering new opportunities to understand disease mechanisms 96 (Vincent et al., 2015; Huang et al., 2011). Furthermore, the growing repository of clinical trial data, 97 alongside extensive literature, serves as a valuable resource for identifying targets and generating 98 hypotheses to inform the drug discovery process (Lysenko et al., 2018).

99 Here, we present TICTAC (Target Illumination Clinical Trial Analytics with Cheminformatics), an 100 application designed to illuminate understudied drug targets by leveraging aggregated data from 101 AACT. TICTAC enables ranking, filtering, and interpretation of inferred disease-target associations, 102 assigning scores derived from aggregated evidence linking diseases to protein-coding genes mapped 103 from drugs. This study outlines the analytical framework and interpretability of TICTAC, addressing 104 statistical and semantic challenges. TICTAC demonstrates the application of data science in achieving 105 scientific consensus and improving interpretability. The validation of disease-target associations is critical for ensuring the accuracy and reliability of biomedical datasets. This study also presents a 106 107 methodology for validating the TICTAC disease-gene associations against MedlineGenomics 108 (formerly Genetics Home Reference) by leveraging standardized disease terminologies, such as 109 Disease Ontology IDs (DOIDs) (Schriml et al., 2022) and UMLS Concept Unique Identifiers (CUIs) 110 (McInnes et al., 2007). By comparing disease-target associations across these datasets, the aim is to 111 quantify overlap, identify areas of divergence, and provide insights into the consistency and reliability 112 of the two data sources.

113

#### 114 2 Material & Methods

#### 115 2.1 AACT Data Preprocessing

The initial step in our methodology involved applying NextMove LeadMine (version 3.14.1). LeadMine, developed by NextMove Software, is a commercial text mining tool that identifies and annotates chemical entities, protein targets, genes, diseases, species, and more using curated grammars and dictionaries with advanced capabilities like correcting misspelled terms with CaffeineFix technology and supports chemical entity recognition in multiple languages, including Chinese and

121 Japanese(Lowe & Sayle, 2015). This tool was utilized to analyze intervention names and study 122 descriptions retrieved from ClinicalTrials.gov, enabling the identification of unique drug names and 123 their corresponding SMILES (Simplified Molecular Input Line Entry System) representations. However, many terms encountered, such as "placebo," "test product," "medication," and 124 125 "chemotherapy," lacked specific structural chemical information. For disease-named entity recognition (NER), we leveraged the JensenLab Tagger (Cook & Jensen, 2019). The JensenLab Tagger is a 126 127 dictionary-based NER tool designed to identify and annotate entities such as genes, proteins, species, diseases, and other biomedical terms within text. It has been instrumental in text-mining applications, 128 129 including extracting protein-protein interactions and annotating biomedical literature. The source code 130 is available on GitHub: https://github.com/larsjuhljensen/tagger. This tool was applied to trial 131 descriptions to identify and categorize diseases, resolving disease mentions to standardized terms in 132 the Disease Ontology (DOID). This enhanced the consistency and granularity of disease data across 133 sources. Subsequently, compound-target mapping was conducted to identify potential drug targets. 134 Chemical entities were mapped to PubChem(Kim et al., 2021) using the PUG REST API with 135 SMILES-based exact search and to ChEMBL(Zdrazil et al., 2024) using REST API queries via 136 InChIKey. Biological targets were then mapped from ChEMBL bioassays and linked to the Integrated 137 Disease-Target Knowledgebase (IDG-TCRD/Pharos)(Sheils et al., 2021) using UniProt IDs (The 138 UniProt Consortium, 2023). This systematic mapping established relationships between chemical 139 entities, their biological targets, and associated diseases, forming a foundation for data aggregation 140 efforts.

Our dataset, extracted from the Aggregate Analysis of ClinicalTrials.gov (AACT) database as of September 30, 2024, comprised 507,584 studies, each identified by a unique NCT\_ID. These studies referenced 901,776 publications, associated with 632,153 PubMed IDs (PMIDs) and 127,455 RESULT-type references, spanning 170,697 unique NCT\_IDs. For drug-related data, 133,760 unique drug names were linked to 365,878 unique intervention IDs. It is worth noting that individual NCT\_IDs often referenced multiple drugs, with synonymous naming conventions contributing to challenges in precise drug identification.

148 Our analysis focused exclusively on interventional drug studies, excluding observational studies. Of 149 the total dataset, 388,958 (76.6%) studies were classified as interventional, with 177,780 designated as 150 interventional drug studies, each linked to a unique NCT ID. To refine the chemical data, NextMove LeadMine was used to resolve drug names into standardized chemical structures via SMILES notation. 151 152 This process identified 6,595 unique SMILES associated with 23,982 unique intervention IDs and 153 19,662 unique drug names. The resulting dataset included 901,776 study references and 632,153 154 PubMed IDs, offering a robust basis for linking identified entities in clinical trial data to biomedical literature. 155

156

#### 157 2.2 Computations for Disease-Target Associations

- 158 nStudyNewness
- 159 The **nStudyNewness** metric quantifies the recency-weighted relevance of clinical studies associated
- with each disease-gene pair, reflecting the higher impact of newer studies. This is achieved using anexponential decay function that prioritizes recent studies.
- 162

$$w_i = 2^{e-ti/h}$$

This is a provisional file, not the final typeset article

- 163 where:
- 164  $t_i$  is the age of the study in years,
- h is the half-life determining the decay rate (h = 5 years for studies ≤ 10 years old and h=10 years for older studies).
- 167 The total nStudyNewness for a disease-target pair is:
- 168 nStudyNewness =  $\sum_{n=1}^{N} (w_i)$
- 169 where N is the total number of studies associated with the disease-target pair.

170

# 17nPublicationWeighted

- 172 The **nPublicationWeighted** metric assigns weights to publications based on their reference type,
- accounting for their varying levels of impact on disease-target associations. For each publication *i*
- 174 with reference type  $r_i$ , the weight  $w_i$  is defined as:
- 175  $w_i$ =1.0: If the publication reference type  $r_i$  is a **Result** (denoted by 0.0), it is given the highest weight.
- $w_i=0.5$ : If  $r_i$  is a **Background** reference (denoted by 1.0), it is assigned a medium weight.
- $w_i = 0.25$ : If  $r_i$  is a **Derived** reference (denoted by 2.0), it is given the lowest weight.

# 179 Ranking Associations

- To facilitate the prioritization of disease-gene associations, rankings are computed based on multiplemetrics, culminating in an overall score.
- 1821. Rank Computation: For each metric (nDiseases, nDrug, nStud, nPub, nStudyNewness,183nPublicationWeighted), the rank  $R_{m,j}$  for disease-target pair j is computed in descending184order:

185 
$$R_{m,i} = \operatorname{Rank}(m,j)$$

186 2. Mean Rank: The average rank across all metrics for a disease-target pair *j* is:

187 meanRank<sub>j</sub> = 
$$\frac{1}{K} \sum_{n=1}^{K} R_{m,j}$$

188 where *K* is the total number of metrics.

# 189 3. **Percentile Rank:** Percentile rank is calculated to normalize the meanRank values:

190 percentileMeanRank<sub>j</sub> = 
$$\frac{1}{N}$$
 Rank(meanRank<sub>j</sub> x 100  
191 where N is the total number of disease-target pairs.

192 4. Mean Rank Score: The final mean rank score, providing a scale from 0 to 100, is:

193 194

195 This methodology ensures inferred disease-target associations are systematically ranked based on

- 196 multiple evidence metrics, with the highest meanRankScore indicating the most promising targets for
- 197 further research and development.

#### 198 2.3 Validation Method

199 The validation methodology included key steps to map and compare disease-target associations 200 between TICTAC and MedlinePlus Genetics (MedlineGenomics) (U.S. National Library of Medicine, 201 n.d). The mapping from Disease Ontology was processed to link DOIDs with UMLS CUIs and validate 202 data integrity through unique counts. MedlinePlus genetics conditions were formatted to align with 203 these mappings, ensuring compatibility and accuracy. TICTAC disease-target associations were 204 similarly prepared by standardizing identifiers, refining data fields, and verifying counts of key entities. 205 Common CUIs between datasets were identified, and their corresponding associations were extracted 206 for comparison. Overlaps between the datasets were evaluated by analyzing shared associations, with the percentage of MedlinePlus Genetics associations present in TICTAC calculated. The validation 207 208 assessed dataset integrity, overlap in conditions (common CUIs), and overlap in disease-target 209 associations to measure alignment and reliability.

210

### 211 **3** Results

### 212 **3.1 The TICTAC Application**

TICTAC supports drug target identification by scoring and ranking associations between drug targets (protein-coding genes) and diseases. The TICTAC workflow aggregates and filters inferred clinical trial findings to generate actionable insights. These insights can be leveraged to enhance target prioritization through interactive visualizations and hit lists (Fig. 2), enabling users to identify the strongest, evidence-supported associations.

218 Hits in the TICTAC dashboard are ranked by meanRankScore, as described in Section 2. The 219 scatterplot presents evidence (meanRankScore) on the X-axis versus publication count (nPub) on the 220 Y-axis, visually representing disease-target associations. The workflow allows users to filter results 221 using query parameters such as disease terms (e.g., "type 2 diabetes/insulin resistance," DOID:9352) 222 and gene symbols. Data points in the scatterplot are colored by target development level (TDL), a 223 knowledge-based classification system that categorizes human proteins into four distinct groups (Oprea 224 et al., 2018) as Tclin (Santos et al., 2017), Tchem, Tbio, and Tdark for the comprehensiveness of 225 exploration from clinical, chemical, and biological perspectives. This framework enables the 226 prioritization of disease-target pairs based on their evidence levels and functional classifications, 227 facilitating drug discovery efforts and identifying novel targets for further research.

228

# 229 3.2 Agreement-Based Validation of TICTAC and MedlinePlus Genetics Datasets

The agreement-based validation process revealed that the TICTAC dataset includes 2,243 unique Disease Ontology IDs (DOIDs) and 2,022 unique gene symbols, while the MedlinePlus Genetics dataset contains 1,216 conditions mapped to Concept Unique Identifiers (CUIs) and 2,142 unique CUIs. A total of 193 CUIs were shared between the two datasets, allowing for a comparative analysis

- of associations. For the shared CUIs, the TICTAC dataset encompassed 63,569 associations involving
- 235 1,804 gene symbols, whereas the MedlinePlus Genetics dataset comprised 1,247 associations involving

236 967 gene symbols. Notably, 136 associations overlapped between the two datasets, accounting for

237 10.91% of the MedlinePlus Genetics associations. This indicates that the TICTAC dataset contains a

high proportion of novel associations, with an estimated 89% of associations being unique to TICTAC.
 These results highlight the potential of the TICTAC dataset to contribute significant novel insights,

while also demonstrating consistency between the datasets for a subset of shared associations. This

- agreement-based approach underscores the complementary nature of these resources and the value of
- 241 agreement-based approach underscores the complementary nature of these resources and the value of 242 TICTAC for expanding the landscape of disease target associations for further investigation
- 242 TICTAC for expanding the landscape of disease-target associations for further investigation.
- 243

# 244 **3.3** Using TICTAC for Drug Target Illumination

# 3.3.1 Exploring Understudied Genes in Type2 Diabetes/Insulin Resistance: Integrating Metrics for Target Discovery Potential

247 Fig. 3 highlights examples of understudied (Tbio) genes associated with "type 2 diabetes/insulin 248 resistance" within the TICTAC framework. The analysis focuses on genes classified as Tbio, indicating 249 they are less characterized and have limited research attention compared to more 'established targets'. 250 The table provides key metrics for each gene-disease pair, including the number of diseases 251 (nDiseases), drugs (nDrug), studies (nStud), and publications (nPub), along with evidence 252 prioritization scores such as nStudyNewness and meanRankScore. These metrics collectively illustrate 253 the relative evidence strength and research activity for each gene-disease pair. The analysis reveals 254 significant variability in the evidence supporting these genes. For instance, some genes, such as 255 UGT1A10 (41 publications, meanRankScore = 97.87784), have substantial supporting evidence, while 256 others, such as COQ8A (0 publications, meanRankScore = 46.33545), remain less explored in the 257 literature. Importantly, all listed genes have some level of therapeutic association, as reflected in the 258 nDrug column, which indicates the number of drugs linked to each gene. For example, MAP4K4 and 259 RAC1 are linked to drugs such as Sorafenib and Dasatinib, while other genes, such as CISD2, are 260 associated with broader therapeutic contexts. The nStudyNewness metric emphasizes the relevance of 261 recent evidence for these gene-disease pairs, with genes like CISD2 demonstrating strong support from 262 newer studies and achieving a high meanRankScore (98.92213). Such metrics underscore the potential 263 for these Tbio genes to serve as new therapeutic targets for metabolic disorders. Genes with high 264 meanRankScore and robust evidence, such as CISD2, may warrant further investigation in drug 265 discovery efforts. Conversely, genes with minimal publications, such as COQ8A, represent 266 opportunities for expanding research into their roles in type 2 diabetes and insulin resistance. 267

Overall, this analysis of Tbio genes in the context of type 2 diabetes/insulin resistance highlights the utility of TICTAC in identifying and prioritizing understudied targets for further research and therapeutic development. By integrating metrics such as meanRankScore, nPub, and nStudyNewness, the framework enables systematic exploration of gene-disease associations, providing actionable insights for drug discovery.

273

# 3.3.2 Integrating Evidence for Disease-Target Associations: Insights from the TICTAC Provenance Dashboard

Figure 4 presents the TICTAC Provenance Dashboard, which provides detailed reference data supporting the association between the MCR4 (Melanocortin receptor 4) gene and type 2 diabetes/insulin resistance (DOID:9352). This dashboard aggregates references from clinical trials and publications, offering comprehensive insights into the evidence linking the gene to the disease. The framework for the provenance of this association includes several key elements. The **nct\_id** column lists unique identifiers for clinical trials, while the **reference type** column categorizes evidence as

BACKGROUND (contextual information), RESULT (direct findings), or DERIVED (secondary findings). The **pmid** column includes PubMed IDs linking to corresponding publications, and the **citation** column provides bibliographic details such as titles, authors, journals, and publication years. The results reveal a mix of evidence types. BACKGROUND references highlight physiological mechanisms like insulin sensitivity and glucose metabolism foundational to type 2 diabetes research. RESULT references contribute direct findings, such as variability in cyclooxygenase inhibition in aspirin studies, while DERIVED references explore broader evidence, such as anti-psychotropic

- 289 medication usage. For example, Larsen et al. (2012) offer insights into diabetes mechanisms.
- 290

291 Sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as a novel therapeutic approach for 292 type 2 diabetes, particularly in improving cardiovascular outcomes. These inhibitors reduce myocardial 293 glucose uptake by up to 57%, inducing metabolic shifts toward fatty acid utilization (Lauritsen et al., 294 2021). Additionally, they lower myocardial blood flow (MBF) by approximately 13%, potentially due 295 to diuretic effects that reduce blood pressure and alter renal hemodynamics (Kimura, 2016). While 296 SGLT2 inhibitors significantly mitigate glucose uptake and blood flow, their broader cardioprotective 297 effects likely involve mechanisms beyond these metrics. For example, they do not notably alter 298 myocardial oxygen consumption, suggesting additional pathways are at play (Lauritsen et al., 2021; 299 Huang et al., 2023). Despite these complexities, improved cardiac function and reduced heart failure 300 risk highlight their therapeutic potential (Huang et al., 2023). A strong hypothesis thus emerges: 301 SGLT2 inhibition improves cardiac outcomes in individuals with type 2 diabetes by inducing metabolic 302 shifts, reducing myocardial blood flow, and enhancing cardiac efficiency. This framework underscores the importance of integrating diverse evidence types to establish robust disease-target associations. 303 304 Direct access to clinical trial identifiers and PubMed references enhances reproducibility and 305 credibility, making the TICTAC Provenance Dashboard a valuable resource for researchers exploring 306 therapeutic targets in type 2 diabetes.

#### 307 **3.3.3 Mapping Disease-Target Associations and Evidence in Lung Cancer Research**

Figures 5 and 6 provide a comprehensive view of gene-disease associations related to lung cancer (DOID:1324), focusing on potential gene targets and the provenance of specific evidence linking the PGR (Progesterone receptor, UniProt: P06401) gene to the disease.

311

312 Figure 5 presents the TICTAC Disease-Target Dashboard, which highlights key metrics for genes 313 associated with lung cancer. The dashboard includes metrics such as the number of diseases 314 (nDiseases), drugs (nDrug), studies (nStud), and publications (nPub) related to each gene-disease pair. 315 Additional evidence metrics such as nStudyNewness, which prioritizes recent studies, and 316 PublicationWeight, which accounts for the relevance of evidence, are also shown. The meanRankScore 317 provides a composite metric ranking associations based on the strength and quality of evidence. For 318 each gene, the dashboard also lists the associated drugs and Target Development Level (TDL), a 319 classification reflecting the druggability of the gene. Notable findings include highly ranked genes such 320 as ADK (meanRankScore = 97.73276) and BDKRB2 (meanRankScore = 95.97179), which are 321 supported by robust evidence from multiple studies, publications, and associated drugs. 322 Therapeutically, drugs such as Abemaciclib, 5-Fluorouracil, and Carboplatin are frequently linked to 323 the listed genes, emphasizing their relevance to lung cancer treatment. The genes in this dashboard are 324 classified as Tchem, indicating their known potential as druggable targets, making this dashboard a

325 critical resource for prioritizing genes with strong evidence for further exploration in lung cancer 326 research and therapeutic development.

327

328 Figure 6 provides detailed evidence provenance for the association between the PGR (Progesterone 329 receptor) gene and lung cancer. The TICTAC Provenance Dashboard aggregates references from 330 clinical trials and publications to trace the supporting evidence. It includes clinical trial identifiers 331 (nct id), 2978 reference types categorized as RESULT for direct findings or BACKGROUND for 332 supporting evidence, PubMed IDs (pmid), and detailed citations for each referenced study. The 333 provenance dashboard reveals that the association between PGR and lung cancer is supported by both 334 direct results and background studies. These references detail the role of therapies such as carboplatin 335 in treating lung cancer, providing clinical context for PGR's relevance. This detailed provenance 336 ensures the traceability of the data and supports further exploration of PGR in lung cancer research.

337

Taken together, Figures 5 and 6 illustrate the utility of TICTAC in mapping disease-target associations and integrating comprehensive evidence provenance. The TICTAC Disease-Target Dashboard enables the identification of high-priority gene targets and associated drugs, while the Provenance Dashboard provides detailed and traceable evidence for specific genes like PGR. This combination of tools allows for a robust prioritization framework, supporting translational research and advancing the discovery of potential therapeutic targets.

344

#### 345 4 Discussion

#### 346 4.1 Illuminating Knowledge Gaps in Targets

The National Institutes of Health's (NIH) Illuminating the Druggable Genome (IDG) program is dedicated to advancing our understanding of understudied proteins within pivotal druggable families, including G-protein-coupled receptors (GPCRs), ion channels, and protein kinases (National Institutes of Health, 2024). By elucidating the roles of these proteins in health and disease, the program seeks to identify novel therapeutic targets and foster innovative drug development strategies.

352

353 For a detailed exploration of the objectives and methodologies of the IDG program, refer to 354 "Unexplored therapeutic opportunities in the human genome" by Oprea et al. (Oprea et al., 2018). 355 TICTAC aligns seamlessly with this mission, focusing on evaluating clinical trial evidence to reveal 356 disease-target associations. Unlike other platforms, such as Open Targets (Ghoussaini et al., 2021; 357 Ochoa et al., 2021), which leverage a blend of data, supervised machine learning, and external sources, 358 TICTAC strictly aggregates evidence from the AACT database. This approach minimizes biases 359 inherent in curated training data and domain-specific assumptions, offering interpretable results that 360 are grounded in experimental provenance and reproducible methodologies. By integrating its 361 automated, sustainable workflow into resources such as the Pharos portal (Nguyen et al., 2017; Sheils 362 et al., 2021), TICTAC complements existing tools for target illumination. While Open Targets supports 363 scientists by enhancing associations with external validation, TICTAC prioritizes the rigor of direct

clinical trial data. This makes it particularly suited for downstream users who require traceable,transparent insights into disease-target relationships.

366

#### 367 **4.2 Transforming Data into Actionable Knowledge**

In genomics and drug discovery, where data overload is a persistent challenge, transforming raw 368 information into actionable knowledge remains critical. Specialized tools aid in uncovering insights, 369 370 but the interpretation and integration of these findings often demand expertise that non-specialists may 371 lack. TICTAC addresses this gap by introducing a layer of abstraction that is not only accessible but also directly aligned with the objectives of drug discovery scientists. TICTAC's design philosophy 372 373 rests on simplicity and scientific axioms, such as prioritizing evidence from independent confirmatory 374 results (Yang et al., 2021). This emphasis ensures the interpretability of findings and highlights clinical 375 trial results as a cornerstone of evidence-based reasoning. While correlation does not equate to 376 causation, it builds a foundation of plausibility, fostering hypothesis generation and prioritization. With this context in mind, TICTAC provides a pragmatic, rational framework for ranking research 377 378 hypotheses. Clinical trials are often influenced by experimental noise and systematic uncertainties 379 stemming from factors like the COVID-19 pandemic's impact on follow-ups (Servick, 2020), 380 incomplete data from missing participants (Verzilli & Carpenter, 2002), and biases in endpoint 381 evaluations (Chen et al., 2020). Ambiguities in defining study populations and inadequate reporting of 382 sample sizes further complicate result interpretation (Frampton & Shepherd, 2008). Addressing these 383 challenges through improved methodologies and reporting standards is essential to enhance the validity 384 and reliability of trial outcomes. While acknowledging that experimental noise and systematic 385 uncertainties can accompany clinical trial data, the approach ensures that aggregated insights are 386 meaningful and usable for non-specialist stakeholders in drug development.

387

#### **4.3 Designing for Seamless Integration and Confidence**

389 Biomedical knowledge discovery thrives on the integration of diverse, heterogeneous data sources, reflecting the inherent complexity of the field. However, challenges related to provenance, 390 interpretability, and confidence frequently undermine these efforts. TICTAC addresses these concerns 391 392 by employing simple yet robust metrics, such as unbiased meanRank scores, to evaluate and rank 393 disease-target associations. One of TICTAC's key innovations lies in its transparent approach to 394 confidence assessment. By restricting provenance to the linked publications, the platform ensures 395 enhanced interpretability and traceability. This minimalist yet methodical approach reduces the 396 accumulation of errors and confidence decay that often plague systems integrating multiple, 397 heterogeneous data sources. Continuous confidence scores allow for dynamic algorithmic weighting 398 and filtering, supporting downstream applications that require both precision and flexibility. The clear 399 use of standardized identifiers and semantics strengthens integration across biomedical resources, 400 paving the way for consistent cross-platform compatibility. Figure 7 illustrates TICTAC's workflow 401 and interfaces, underscoring its defined role in disease-target discovery pipelines. With its focus on 402 transparency, interpretability, and confidence, TICTAC offers a practical and scientifically rigorous 403 tool for advancing biomedical research and drug discovery.

404

#### 405 4.4 Validation

The validation process revealed a 10.91% overlap between MedlineGenomics and TICTAC diseasegene associations for the 193 shared CUIs, indicating some level of consistency while also highlighting significant differences between the datasets. These discrepancies arise from variations in data collection methods, terminological standards, and the granularity of gene-disease associations. The low percentage of overlap underscores the need for improved standardization in disease-gene datasets. This

411 process emphasized the value of standardized identifiers such as DOIDs and CUIs for aligning and

- 412 comparing biomedical data. It also highlighted potential gaps in data completeness or detail, which 413 could affect the utility of these datasets in downstream research, and reinforced the importance of
- 414 integrating multiple sources to achieve a comprehensive understanding of disease-gene relationships.
- 415

### 416 5 Conclusion

417 The conventional "one gene, one function, one trait" paradigm, as critiqued by Visscher et al. (2017), 418 is no longer adequate for understanding the intricate mechanisms underlying diseases. This shift in 419 understanding highlights the need for advanced tools that can navigate the multifaceted nature of 420 genetic and clinical data, enabling researchers to uncover meaningful relationships between genes, 421 traits, and diseases (Yang et al., 2021). Modern biomedical research demands tools that move beyond 422 oversimplifications to provide actionable insights grounded in real-world data. TICTAC rises to this 423 challenge by offering a dynamic platform tailored for drug target hypothesis generation and refinement, 424 leveraging clinical trial data and metadata to bridge the gap between data complexity and practical 425 application. Aligned with the increasing focus on interpretable machine learning and explainable 426 artificial intelligence (XAI) (Adadi & Berrada, 2018), TICTAC employs transparent, evidence-driven 427 methodologies to elucidate disease-target associations. Its foundation rests solely on clinical trial data 428 and metadata, supported by rational, intuitive evidence metrics, and underpinned by a robust open-429 source pipeline designed for continuous improvement and scalability. TICTAC's adaptability allows 430 it to function either as a standalone resource or as a component integrated with other analytical 431 interfaces. By simplifying the exploration of complex clinical data, TICTAC contributes meaningfully 432 to the identification and prioritization of drug targets, offering a practical and evolving tool for 433 advancing biomedical research and translational science.

# 434 6 Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial
relationships that could be construed as a potential conflict of interest.

437 **7** Author Contributions

# 438 8 Funding

- 439 9 This work was partially supported by US National Institutes of Health [U24 224370]
  440 'Illuminating the Druggable Genome Knowledge Management Center' (IDG KMC).
- 441 **10** Acknowledgments

# 442 11 Reference

443Zarin, D. A., & Ide, N. C. (2005). Registering a clinical trial in ClinicalTrials.gov. Chest,444128(1), 319–323.

445 446	Tse, T., Fain, K. M., & Zarin, D. A. (2018). How to avoid common problems when using ClinicalTrials.gov in research: 10 issues to consider. BMJ, 361, k1452.
447 448	Laine, C., Horton, R., DeAngelis, C. D., et al. (2007). Clinical trial registration: Looking back and moving ahead. New England Journal of Medicine, 356(26), 2734–2736.
449 450 451	Riveros, C., Dechartres, A., Perrodeau, E., et al. (2013). Timing and completeness of trial results posted at ClinicalTrials.gov and published in journals. PLoS Medicine, 10(12), e1001566.
452 453	Prayle, A. P., Hurley, M. N., & Smyth, A. R. (2012). Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: Cross sectional study. BMJ, 344, d7373.
454 455	DeVito, N. J., Bacon, S., & Goldacre, B. (2020). Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: A cohort study. Lancet, 395(10221), 361–369.
456 457	Wilkinson, M. D., Dumontier, M., Aalbersberg, I. J., et al. (2016). The FAIR Guiding Principles for scientific data management and stewardship. Scientific Data, 3, 160018.
458 459 460 461	Tasneem, A., Aberle, L., Ananth, H., Chakraborty, S., Chiswell, K., McCourt, B. J., & Pietrobon, R. (2012). The Database for Aggregate Analysis of ClinicalTrials.gov (AACT) and Subsequent Regrouping by Clinical Specialty. PLoS ONE, 7(3), e33677. https://doi.org/10.1371/journal.pone.0033677
462 463 464	Moffat, J. G., Vincent, F., Lee, J. A., Eder, J., & Prunotto, M. (2017). Opportunities and challenges in phenotypic drug discovery: an industry perspective. Nature Reviews Drug Discovery, 16(8), 531-543.
465 466	Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012). Diagnosing the decline in pharmaceutical R&D efficiency. Nature Reviews Drug Discovery, 11(3), 191-200.
467 468	Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014). Clinical development success rates for investigational drugs. Nature Biotechnology, 32(1), 40-51.
469 470	Ledford, H. (2011). Drug candidates derailed in case of mistaken identity. Nature, 480(7378), 161-162.
471 472 473	Liu, Q., Liu, Q., Zhang, J., Tao, C., Shen, F., & Wang, Y. (2021). Predicting the clinical outcomes of phase II/III trials for cancer drugs using the drug's mechanism of action: a database analysis. Scientific Reports, 11(1), 1239.
474 475	Dahlin, J. L., Inglese, J., & Walters, M. A. (2015). Mitigating risk in academic preclinical drug discovery. Nature Reviews Drug Discovery, 14(4), 279-294.
476 477	Muller, P. Y., & Milton, M. N. (2012). The determination and interpretation of the therapeutic index in drug development. Nature Reviews Drug Discovery, 11(10), 751-761.
478 479 480	Vincent, F., Loria, P., Pregel, M., Stanton, R., Kitching, L., Nocka, K., Doyonnas, R., Steppan, C., Gilbert, A., Schroeter, T., & Peakman, M. C. (2015). High-throughput screening (HTS) and multi-parametric data analysis: challenges and promises. Frontiers in Pharmacology, 6, 157.

Huang, R., Southall, N., Wang, Y., Yasgar, A., Shinn, P., Jadhav, A., Nguyen, D. T., & Austin,
C. P. (2011). The NCGC pharmaceutical collection: a comprehensive resource of clinically
approved drugs enabling repurposing and chemical genomics. Science Translational Medicine,
3(80), 80ps16.
Lysenko, I., Kim, H. Y., Emili, A., & Schlessinger, A. (2018). Predicting adverse drug events

- 485 Lysenko, I., Kim, H. Y., Emili, A., & Schlessinger, A. (2018). Predicting adverse drug events
  486 by relational learning on clinical notes. Journal of the American Medical Informatics
  487 Association, 25(3), 246-253.
- Schriml, L. M., Munro, J. B., Schor, M., Olley, D., McCracken, C., Felix, V., Baron, J. A.,
  Jackson, R., Bello, S. M., Bearer, C., Lichenstein, R., Bisordi, K., Dialo, N. C., Giglio, M., &
  Greene, C. (2022). The Human Disease Ontology 2022 update. Nucleic Acids Research,
  50(D1), D1255-D1261. https://doi.org/10.1093/nar/gkab1063
- McInnes, B. T., Pedersen, T., & Carlis, J. V. (2007). Using UMLS Concept Unique Identifiers
  (CUIs) for Word Sense Disambiguation in the Biomedical Domain. AMIA Annual Symposium
  Proceedings, 533-537
- Lowe, D. M., & Sayle, R. A. (2015). LeadMine: A grammar and dictionary driven approach to
  entity recognition. Journal of Cheminformatics, 7(Suppl 1), S5. <u>https://doi.org/10.1186/1758-</u>
  2946-7-S1-S5
- 498 Cook, H. V., & Jensen, L. J. (2019). A guide to dictionary-based text mining. In R. Larson & T.
  499 Oprea (Eds.), Bioinformatics and drug discovery (pp. 57-75). Humana Press.
  500 https://doi.org/10.1007/978-1-4939-9089-4 5
- Kim, S., Chen, J., Cheng, T., Gindulyte, A., He, J., He, S., Li, Q., Shoemaker, B. A., Thiessen,
  P. A., Yu, B., Zaslavsky, L., Zhang, J., & Bolton, E. E. (2021). PubChem in 2021: new data
  content and improved web interfaces. Nucleic Acids Research, 49(D1), D1388-D1395.
  https://doi.org/10.1093/nar/gkaa971
- Zdrazil, B., Felix, E., Hunter, F., Manners, E. J., Blackshaw, J., Corbett, S., de Veij, M.,
  Ioannidis, H., Lopez, D. M., Mosquera, J. F., Magarinos, M. P., Bosc, N., Arcila, R., Kizilören,
  T., Gaulton, A., Bento, A. P., Adasme, M. F., Monecke, P., Landrum, G. A., & Leach, A. R.
  (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple
  bioactivity data types and time periods. Nucleic acids research, 52(D1), D1180–D1192.
  https://doi.org/10.1093/nar/gkad1004
- Sheils, T. K., Mathias, S. L., Kelleher, K. J., Siramshetty, V. B., Nguyen, D.-T., Bologa, C. G.,
  Jensen, L. J., Vidović, D., Koleti, A., Schürer, S. C., Waller, A., Yang, J. J., Holmes, J., Bocci,
  G., Southall, N., Dharkar, P., Mathé, E., Simeonov, A., & Oprea, T. I. (2021). TCRD and
  Pharos 2021: mining the human proteome for disease biology. Nucleic Acids Research,
  49(D1), D1334–D1346. https://doi.org/10.1093/nar/gkaa993
- 516The UniProt Consortium. (2023). UniProt: the Universal Protein Knowledgebase in 2023.517Nucleic Acids Research, 51(D1), D523-D531. https://doi.org/10.1093/nar/gkac1052
- 518 U.S. National Library of Medicine. (n.d.). Genetics. MedlinePlus. Retrieved December 11,
   519 2024, from https://medlineplus.gov/genetics/

520 521 522 523 524	Oprea, T. I., Bologa, C. G., Brunak, S., Campbell, A., Gan, G. N., Gaulton, A., Gomez, S. M., Guha, R., Hersey, A., Holmes, J., Jadhav, A., Jensen, L. J., Johnson, G. L., Karlson, A., Leach, A. R., Ma'ayan, A., Malovannaya, A., Mani, S., Mathias, S. L., Zahoránszky-Köhalmi, G. (2018). Unexplored therapeutic opportunities in the human genome. Nature Reviews Drug Discovery, 17(5), 317-332. https://doi.org/10.1038/nrd.2018.14
525 526 527 528	Santos, R., Ursu, O., Gaulton, A., Bento, A. P., Donadi, R. S., Bologa, C. G., Karlsson, A., Al-Lazikani, B., Hersey, A., Oprea, T. I., & Overington, J. P. (2017). A comprehensive map of molecular drug targets. Nature reviews. Drug discovery, 16(1), 19–34. https://doi.org/10.1038/nrd.2016.230
529 530 531 532 533	Lauritsen, K. M., Nielsen, B. R. R., Tolbod, L. P., Johannsen, M., Hansen, J., Hansen, T. K., Wiggers, H., Møller, N., Gormsen, L. C., & Søndergaard, E. (2021). SGLT2 inhibition does not affect myocardial fatty acid oxidation or uptake, but reduces myocardial glucose uptake and blood flow in individuals with type 2 diabetes: A randomized double-blind, placebo-controlled crossover trial. Diabetes, 70(3), 800-808. https://doi.org/10.2337/db20-0921
534 535 536	Kimura, G. (2016). Importance of inhibiting sodium-glucose cotransporter and its compelling indication in type 2 diabetes: Pathophysiological hypothesis. Journal of the American Society of Hypertension: JASH, 10(3), 271–278. https://doi.org/10.1016/j.jash.2016.01.009
537 538 539	Huang, K., Luo, X., Liao, B., & et al. (2023). Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: Focus on the mechanisms. Cardiovascular Diabetology, 22(86). https://doi.org/10.1186/s12933-023-01816-5
540 541	National Institutes of Health. (2024, December 2). Illuminating the Druggable Genome (IDG). https://commonfund.nih.gov/idg
542 543 544 545 546 547	Nguyen, D. T., Mathias, S., Bologa, C., Brunak, S., Fernandez, N., Gaulton, A., Hersey, A., Holmes, J., Jensen, L. J., Karlsson, A., Liu, G., Ma'ayan, A., Mandava, G., Mani, S., Mehta, S., Overington, J., Patel, J., Rouillard, A. D., Schürer, S., Sheils, T., Simeonov, A., Sklar, L. A., Southall, N., Ursu, O., Vidovic, D., Waller, A., Yang, J., Jadhav, A., & Oprea, T. I. (2017). Pharos: Collating protein information to shed light on the druggable genome. Nucleic Acids Research, 45(D1), D995–D1002. https://doi.org/10.1093/nar/gkw1072
548 549 550 551 552 553	Ghoussaini, M., Mountjoy, E., Carmona, M., Peat, G., Schmidt, E. M., Hercules, A., Fumis, L., Miranda, A., Carvalho-Silva, D., Buniello, A., Burdett, T., Hayhurst, J., Baker, J., Ferrer, J., Gonzalez-Uriarte, A., Jupp, S., Karim, M. A., Wright, D., Suveges, D., & Dunham, I. (2021). Open Targets Genetics: systematic identification of trait-associated genes using large-scale genetics and functional genomics. Nucleic Acids Research, 49(D1), D1311–D1320. https://doi.org/10.1093/nar/gkaa840
554 555 556 557 558 559	Ochoa, D., Hercules, A., Carmona, M., Suveges, D., Gonzalez-Uriarte, A., Malangone, C., Miranda, A., Fumis, L., Carvalho-Silva, D., Spitzer, M., Peat, G., Baker, J., Ferrer, J., Raies, A., Wright, D., Imker, H. J., Schwartzentruber, J., Hulcoop, D. G., McDonagh, E. M., & Dunham, I. (2021). Open Targets Platform: Supporting systematic drug-target identification and prioritisation. Nucleic Acids Research, 49(D1), D1302–D1310. https://doi.org/10.1093/nar/gkaa1027

560		Sheils, T. K., Mathias, S. L., Kelleher, K. J., Siramshetty, V. B., Nguyen, DT., & Bologa, C.
561 562		G. (2021). TCRD and Pharos 2021: Mining the human proteome for disease biology. Nucleic Acids Research, 49(D1), D1334–D1346. https://doi.org/10.1093/nar/gkaa993
563		Yang, J. J., Grissa, D., Lambert, C. G., Bologa, C. G., Mathias, S. L., Waller, A., Wild, D. J.,
564		Juhl Jensen, L., & Oprea, T. I. (2021). TIGA: target illumination GWAS analytics.
565		Bioinformatics, 37(21), 3865–3873. https://doi.org/10.1093/bioinformatics/btab427
566		Servick, K. (2020). Pandemic could add noise to clinical trial data. Science, 368(6492), 693.
567		https://doi.org/10.1126/science.368.6492.693
568		Chen, Y., Lawrence, J., Hung, H. M. J., et al. (2021). Methods for employing information
569		about uncertainty of ascertainment of events in clinical trials. Therapeutic Innovation &
570		Regulatory Science, 55(1), 197–211. https://doi.org/10.1007/s43441-020-00206-3
571		Verzilli, C. J., & Carpenter, J. R. (2002). Assessing uncertainty about parameter estimates with
572		incomplete repeated ordinal data. Statistical Modelling, 2(3), 203-215.
573		https://doi.org/10.1191/1471082x02st0330a
574		Chen, Y., Chen, Y., Lawrence, J., Hung, H.M., & Stockbridge, N. (2020). Methods for
575		employing information about uncertainty of ascertainment of events in clinical trials.
576		Therapeutic Innovation & Regulatory Science, 55(1), 197–211.
577		https://doi.org/10.1007/S43441-020-00206-3
578		Frampton, G., & Shepherd, J. (2008). Ambiguity of study population analysis and reporting in
579		asthma clinical trials. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen,
580		102, 52-52. https://doi.org/10.1016/J.ZEFQ.2008.06.015
581		Adadi, A., & Berrada, M. (2018). Peeking inside the black-box: A survey on explainable
582		artificial intelligence (XAI). IEEE Access, 6, 52138-52160.
583		https://doi.org/10.1109/ACCESS.2018.2870052
584	12	Supplementary Material
585	13	Data Availability Statement
586	The	datasets generated and analyzed for this study as well as the source code can be found in the
587	TIC	TAC repository (https://github.com/unmtransinfo/TICTAC)
507	110	
588		
589		
590		
501		
391		
592	Fig.	1. Clinical Trial study counts by year indicating growth and trends





# Fig. 2. TICTAC dashboard. The image displays genes currently associated with the disease 'type 2 diabetes/insulin resistance' (DOID:9352)

#### Interactive TICTAC Disease-Target Dashboard

	idgTDL Filter		Gene Fil	lter			Y-axis Va	ariable							
			Enter	gene name (e	.g., ABCB11)		nPub			•					
	Page Size: 40		Page Nu	umber: 2											
						l aur cui									
	DOID:9352_Q7L2E3 1	1	1	0	0.0	NaN	17.25382	type 2 diabetes Sorafenib	Tchem	DHX30		1	Disease-Target Association		
	1 DOID:9352_P32302 1	1	1	1	0.29	0.25	21.76116	type 2 diabetes Mozobil	Tchem	CXCR5		-		1	
	2 DOID:9352_P41968 31 3 DOID:9352_O9UKV0 7	2	1,160	3,199	1,201.85	1,786.25	94.860756 92.489059	insulin resistan Topiramate type 2 diabetes N-acetyl cyst	Tchem tei Tclin	MC3R HDAC9	30	000 -		X	
	4 DOID:9352_P24385 2	2	4	0	0.0	NaN	40.458111	insulin resistan Genistein	Tchem	CCND1		-		1	
	5 DOID:9352_095263 4	1	4	7	3.27	2.75	64.563164	type 2 diabetes Tadalafil	Tolin	PDE8B	-Q 20	000 -			
	7 DOID:9352_Q9NSY1 2	6	6	0	0.0	NaN	47.88765	type 2 diabetes Alpelisib	Tchem	BMP2K	nPt	1		•••	
	8 DOID:9352_P48736 3	1	7	8	2.42	4.0	66.405647	type 2 diabetes Alpelisib	Tclin	PIK3CG	10	.000		*	
	9 DOID:9352_Q86XP3 1 10 DOID:9352_Q99598 2	2	2	0	0.0	NaN	21.174465 29.779272	type 2 diabetes Quercetin insulin resistan Ellagic Acid	Tchem	DDX42 TSNAX		-			<ul> <li>Tclin</li> <li>Tbio</li> </ul>
	11 DOID:9352_Q8NHB7 1	6	1	23	7.1	12.0	70.390663	type 2 diabetes thymol	Tdark	OR5K1		.1		5	Tchem
	12 DOID:9352_P09960 1 13 DOID:9352 P41595 34	1	1	0	0.0	NaN 1.959.0	17.25382 98.389687	Type 2 diabete Captopril type 2 diabetes empaniifozin	Tchem Tclin	LTA4H		1			<ul> <li>Tdark</li> </ul>
612	14 DOID:9352_P24941 16	1	192	562	198.05	382.5	94.242134	insulin resistan Obeticholic a	ici Tchem	CDK2			20 40 60 80 Evidence (meanRankScore)	100	
•															
(1)															
015															
614															
011															
615															
616															
010															
617															
(10															
018															
619															
<b>()</b>															
620															
621															
021															
622															
672															
023															
624															
( <b>A F</b>															
625															
676															
020															
627															
(10															
028															
629															
<b>()</b>															
630															

# 631 Fig. 3. Examples of understudied (Tbio) genes for disease 'type 2 diabetes/insulin resistance' in

632 TICTAC

#	doid_uniprot	nDiseases	nDrug	nStud	nPub	nStudyNewnes	nPublicationWeigh	meanRankSco	disease_term	drug_name	idgTDL	gene_symbol
0	DOID:9352_Q8NI60	2	5	5	0	0.0	NaN	46.335445	type 2 diabetes	Dasatinib	Tbio	COQ8A
1	DOID:9352_P31152	1	3	2	0	0.0	NaN	31.432911	type 2 diabetes	Sorafenib	Tbio	MAPK4
2	DOID:9352_Q9UBK2	5	1	12	8	2.85	3.75	69.92807	insulin resistan	prednisone	Tbio	PPARGC1A
3	DOID:9352_Q9NRP7	1	4	3	0	0.0	NaN	36.315186	type 2 diabetes	Sorafenib	Tbio	STK36
4	DOID:9352_Q99755	1	4	3	0	0.0	NaN	36.315186	type 2 diabetes	Ruboxistaurin	Tbio	PIP5K1A
5	DOID:9352_P63000	3	2	4	52	15.06	26.25	83.482651	type 2 diabetes	Berberine hydr	Tbio	RAC1
6	DOID:9352_015438	31	1	912	2,396	908.77	1,332.75	94.828827	type 2 diabetes	Pioglitazone	Tbio	ABCC3
7	DOID:9352_Q9HAW8	8	25	42	109	41.03	54.75	97.87738	type 2 diabetes	Bupropion	Tbio	UGT1A10
8	DOID:9352_Q96CH1	6	1	14	30	13.34	16.0	82.17614	type 2 diabetes	Exendin-4	Tbio	GPR146
9	DOID:9352_P21439	3	2	3	2	0.86	0.5	53.197952	insulin resistan	Digoxin	Tbio	ABCB4
10	DOID:9352_000762	2	1	2	39	7.38	19.5	72.307777	type 2 diabetes	Candesartan c	Tbio	UBE2C
11	DOID:9352_Q8NEV4	1	3	2	0	0.0	NaN	31.432911	type 2 diabetes	Dasatinib	Tbio	МҮОЗА
12	DOID:9352_Q01813	2	5	5	0	0.0	NaN	46.335445	type 2 diabetes	Dasatinib	Tbio	PFKP
13	DOID:9352_Q9Y230	1	1	1	0	0.0	NaN	17.25382	type 2 diabetes	Sorafenib	Tbio	RUVBL2
14	DOID:9352_Q14191	3	2	4	14	6.66	9.5	75.701469	type II diabetes	buspirone	Tbio	WRN
15	DOID:9352_P42679	2	1	3	0	0.0	NaN	31.889994	type 2 diabetes	Dasatinib	Tbio	MATK
16	DOID:9352_P23919	1	4	3	5	1.67	3.5	60.488865	insulin resistan	Lamivudine	Tbio	DTYMK
17	DOID:9352_P14859	8	1	33	141	53.55	68.25	91.209229	type 2 diabetes	Pioglitazone	Tbio	POU2F1
18	DOID:9352_Q9H3S4	1	1	1	2	0.37	1.0	29.954967	type II diabetes	Thiamine	Tbio	TPK1
19	DOID:9352_P51843	2	2	7	21	9.32	11.75	78.363693	insulin resistan	Colchicine	Tbio	NR0B1
20	DOID:9352_Q8NA19	1	1	1	0	0.0	NaN	17.25382	type 2 diabetes	oxybutynin	Tbio	L3MBTL4
21	DOID:9352_Q8N5K1	11	5	201	606	202.28	370.25	98.922913	insulin resistan	Pioglitazone	Tbio	CISD2

- 633
- 634
- 635
- 636
- 637
- 638
- ....
- 639
- 640
- 641
- 0.1
- 642
- 643
- 644
- 645
- 646
- 647 Fig. 4. Provenance for association between gene MCR4 (Melanocortin receptor 4

### 648 ) and disease ' type 2 diabetes/insulin resistance'.

				TICTAC Provenance Dashboard DISEASE: DOID:9352 (Type 2 Diabetes/Insulin resistance) GENE: MCR4 (Melanocortin receptor 4)
	Filter by NCT ID	or PMID		Filter by Reference Type
	None			None
	Page Size: 20			Page Number: 1
	nct_id	reference_type	pmid	citation
	NCT02796378	BACKGROUND	21424396	Larsen S, Stride N, Hey-Mogensen M, Hansen CN, Andersen JL, Madsbad S, Worm D, Helge JW, Dela F. Increased mitochondrial substrate sensitivity in skeletal muscle of patients with type 2 diabetes. Diabetologia. 2011 Jun;54(6):1427-36. doi: 10.1007/s00125-011-2098-4. Epub 2011 Mar 18.
	NCT04841096	BACKGROUND	29405543	Khunti K, Kosiborod M, Ray KK. Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: Time to overcome multifactorial therapeutic inertia? Diabetes Obes Metab. 2018 Jun;20(6):1337-1341. doi: 10.1111/dom.13243. Epub 2018 Mar 11.
	NCT04841096	BACKGROUND	28155046	Bianchi C, Daniele G, Dardano A, Miccoli R, Del Prato S. Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes. Drugs. 2017 Mar;77(3):247-264. doi: 10.1007/s40265-017-0694-4.
	NCT05105919	RESULT	20207433	Lordkipanidze M, Pharand C, Schampaert E, Palisaitis DA, Diodati JG. Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease. Int J Cardiol. 2011 Jul 1;150(1):39-44. doi: 10.1016/j.ijcard.2010.02.025. Epub 2010 Mar 7.
	NCT02225834	BACKGROUND	20816828	Piermartiri TC, Figueiredo CP, Rial D, Duarte FS, Bezerra SC, Mancini G, de Bem AF, Prediger RD, Tasca CI. Atorvastatin prevents hippocampal cell death, neuroinflammation and oxidative stress following amyloid-beta(1-40) administration in mice: evidence for dissociation between cognitive deficits and neuronal damage. Exp Neurol. 2010 Dec;226(2):274-84. doi: 10.1016/j.expneurol.2010.08.030. Epub 2010 Sep 15. Erratum In: Exp Neurol. 2021 Nov;345:113840. doi: 10.1016/j.expneurol.2021.113840.
649	NCT02949752	DERIVED	3464644	Gupta B, Chee KS, Neo LQ, Tang C, Hariram J, Tan GC, Verma S, Basu S, Appan DP, Ting CC, Abdin E, Lee J. Effect of aripiprazole as an adjunct to atypical antipsychotics on weight and metabolic profile: a 12-week open-label trial. Ther Adv Psychopharmacol. 2021 Oct 9;11:20451253211046765. doi: 10.1177/20451253211046765. eCollection 2021.
650				
030				
651				
652				
653				
654				
655				
055				
636				
657				
658				
659				
660				
661				
662				
663				
005				
664 665	Fig. 5. 7 (DOID:	TICTAC 1324)	dashb	oard, displaying a plot of genes associated with disease 'lung cancer'

#### Interactive TICTAC Disease-Target Dashboard: DOID:1324

idgTD	L Filter				Gene Filter				Y-axis	Variable			
					Enter gene name	(e.g., ABCB11	)		nPu	b			•
Page	Size: <b>20</b>				Page Number: 1								
#	doid_uniprot	nDiseases	nDrug	nStud	nPub	nStudyNewnes	nPublicationWe	meanRa	ankScor	disease_term	drug_name	idgTDL	gene_symbol
0	DOID:1324_P5	4	16	144	101	45.6	63.25	97.7239	976	lung cancer	Abemaciclib	Tchem	ADK
1	DOID:1324_P0	2	2	16	52	22.36	28.5	86.472	595	lung cancer	5-fluorouracil	Tchem	HSP90AB1
2	DOID:1324_P3	6	170	398	705	277.11	437.25	99.9137	719	lung cancers	Carboplatin	Tclin	BDKRB2
3	DOID:1324_P2	4	9	76	56	22.01	28.25	94.851	616	lung cancer	Dasatinib	Tchem	MAK
4	DOID:1324_Q9	4	45	139	189	81.36	134.0	98.9892	281	lung cancer	Azacitidine	Tbio	ATXN2
5	DOID:1324_Q8	4	1	79	57	22.58	28.5	87.2905	588	lung cancers	Erlotinib	Tchem	HIPK1
6	DOID:1324_P0	1	3	6	2	0.84	2.25	54.9880	091	lung cancer	captopril	Tclin	MME
7	DOID:1324_P2	1	4	7	5	1.57	4.75	64.8662	219	lung cancer	bortezomib	Tchem	MMP8
8	DOID:1324_Q9	1	2	5	2	0.84	2.25	51.4150	077	lung cancer	bortezomib	Tbio	USP18
9	DOID:1324_P3	4	9	76	56	22.01	28.25	94.851	616	lung cancer	Selumetinib	Tchem	TIE1
10	DOID:1324_P4	4	1	80	57	22.58	28.5	87.2979	974	lung cancer	BKM120	Tchem	ZAP70
11	DOID:1324_P2	1	3	2	0	0.0	NaN	31.4329	911	lung cancer	carboplatin	Tclin	RXRB
12	DOID:1324_Q9	1	1	2	3	0.64	1.5	40.5926	606	lung cancer	Pioglitazone	Tchem	CPT1B
13	DOID:1324_P3	4	16	144	101	45.6	63.25	97.7239	976	lung cancer	Erlotinib	Tchem	DNAJA1
14	DOID:1324_P1	6	2	465	762	304.16	480.5	96.7882	269	lung cancers	Dasatinib	Tclin	ADRA2C
15	DOID:1324_Q8	4	1	79	57	22.58	28.5	87.2905	588	lung cancer	Dasatinib	Tchem	DCLK2
16	DOID:1324_P8	5	1	175	224	93.38	154.75	92.895	927	lung cancer	disulfiram	Tchem	SMAD3
17	DOID:1324_P3	6	30	443	718	289.86	462.5	99.858	116	lung cancer	bexarotene	Tclin	ADRA1A
18	DOID:1324_Q8	4	38	83	56	22.01	28.25	95.718	948	lung cancer	Dasatinib	Tbio	VRK2
19	DOID:1324_Q9	4	9	79	57	22.58	28.5	94.9224	193	lung cancer	Dasatinib	Tchem	MARK1

666		Export Data
667		
668		
669		
670		
671		
672		
673		
674		
675		
676	Fig. 6. Provenance for association between <b>PGR</b> gene (Uniprot: P06401) ' <b>Proges</b>	terone receptor

677 and disease 'lung cancer'

		Filter by Reference Type			
Page Size: 20	•	Page Number: 1			
doid_uniprot DOID:1324_P06401	nct_id	RESULT	pmid	citation Thatcher N, Qian W, Girling DJ: Ifosfamide, carboplatin and etoposide with mid- cycle vincristine (ICE-V) versus standard chemotherapy (C) in patients with small cell lung cancer (SCLC) and good performance status (PS): results of an MRC randomized trial (LU21). [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-2489. 619. 2003.	P0640
DOID:1324_P06401	NCT04153734	RESULT	28271869	Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litiere S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, de Vries EGE; RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017 Mar;18(3):e143-e152. doi: 10.1016/S1470-2045(17)30074-8. Epub 2017 Mar 2. Erratum In: Lancet Oncol. 2019 May;20(5):e242. doi: 10.1016/S1470-2045(19)30240-2.	P0640
DOID:1324_P06401	NCT00003299	RESULT	15923572	Niell HB, Herndon JE 2nd, Miller AA, Watson DM, Sandler AB, Kelly K, Marks RS, Perry MC, Ansari RH, Otterson G, Ellerton J, Vokes EE, Green MR; Cancer and Leukemia Group. Randomized phase III intergroup trial of etoposide and cisplatin with or without pacifixavel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol. 2005 Jun 1;23(16):3752-9. doi: 10.1200/JCO.2005.09.071.	P0640
DOID:1324_P06401	NCT00256282	BACKGROUND	21769667	Eroglu Z, Kong KM, Jakowatz JG, Samlowski W, Fruehauf JP. Phase II clinical trial evaluating docetaxel, vinorelbine and GM-CSF in stage IV melanoma. Cancer Chemother Pharmacol. 2011 Oct;68(4):1081-7. doi: 10.1007/s00280- 011-1703-z. Epub 2011 Jul 19.	P0640
DOID:1324_P06401	NCT00509366	BACKGROUND	1705771	Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, Cragun J, Cottrill H, Kelley MJ, Petersen R, Harpole D, Marks J, Berchuck A, Ginsburg GS, Febbo P, Lancaster J, Nevins JR. Genomic signatures to guide the use of chemotherapeutics. Nat Med. 2006 Nov;12(11):1294-300. doi: 10.1038/nm1491. Epub 2006 Oct 22. Erratum In: Nat Med. 2007 Nov;13(11):1388. Nat Med. 2008 Aug;14(8):889.	P064

accessed through the TICTAC github repository. 692



# **TICTAC Workflow**

696